The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
Open accessAbstract
Objective To assess the efficacy and safety of lasmiditan in the acute treatment of migraine. Methods Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo and were asked to treat their next migraine attack within 4 hours of onset. Over 48 hours after dosing, patients used an electronic diary to record headache pain and the presence of nausea, phonophobia, and photophobia, one of which was designated their most bothersome symptom (MBS). Results Of the 1,856 patients who treated an attack, 77.9% had ≥1 cardiovascular risk factors in addition to migraine. Compared with placebo, more patients dosed with lasmiditan 200 mg were free of headache pain at 2 hours after dosing (32.2% vs 15.3%; odds ratio [OR] 2.6, 95% confidence interval [CI] 2.0–3.6, p< 0.001), similar to those dosed with lasmiditan 100 mg (28.2%; OR 2.2, 95% CI 1.6–3.0, p< 0.001). Furthermore, compared with those dosed with placebo, more patients dosed with lasmiditan 200 mg (40.7% vs 29.5%; OR 1.6, 95% CI 1.3–2.1, p< 0.001) and lasmiditan 100 mg (40.9%; OR 1.7, 95% CI, 1.3–2.2, p< 0.001) were free of their MBS at 2 hours after dosing. Adverse events were mostly mild or moderate in intensity. Conclusions Lasmiditan dosed at 200 and 100 mg was efficacious and well tolerated in the treatment of acute migraine among patients with a high level of cardiovascular risk factors. ClinicalTrials.gov identifier NCT02439320. Classification of evidence This study provides Class I evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Ferrari, M. D., Roon, K. I., Lipton, R. B., & Goadsby, P. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06711-3 · Cited by 987
Self-citationAn international study to assess reliability of the Migraine Disability Assessment (MIDAS) score
Stewart, W. F., Lipton, R. B., Whyte, J., Dowson, A., Kolodner, K., Liberman, J. N., & Sawyer, J. (1999) · Neurology · doi:10.1212/wnl.53.5.988 · Cited by 621
Self-citationStewart, W., Lipton, R., Kolodner, K., Liberman, J., & Sawyer, J. (1999) · Cephalalgia · doi:10.1046/j.1468-2982.1999.019002107.x · Cited by 556
Self-citationGuidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators
International Headache Society Clinical Trials Subcommittee members:, Tfelt-Hansen, P., Pascual, J., Ramadan, N., Dahlöf, C., D'Amico, D., Diener, H.-C., Hansen, J. M., Lanteri-Minet, M., Loder, E., et al. (2012) · Cephalalgia · doi:10.1177/0333102411417901 · Cited by 365
Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta‐Analysis
Cameron, C., Kelly, S., Hsieh, S., Murphy, M., Chen, L., Kotb, A., Peterson, J., Coyle, D., Skidmore, B., Gomes, T., et al. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12601 · Cited by 326
Cited by
Ailani, J., Burch, R. C., Robbins, M. S., & the Board of Directors of the American Headache Society (2021) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.14153 · Cited by 766
Migraine and the trigeminovascular system—40 years and counting
Ashina, M., Hansen, J. M., Do, T. P., Melo-Carrillo, A., Burstein, R., & Moskowitz, M. A. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30185-1 · Cited by 606
Ferrari, M. D., Goadsby, P. J., Burstein, R., Kurth, T., Ayata, C., Charles, A., Ashina, M., van den Maagdenberg, A. M. J. M., & Dodick, D. W. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00328-4 · Cited by 500
Hautakangas, H., Winsvold, B. S., Ruotsalainen, S. E., Bjornsdottir, G., Harder, A. V. E., Kogelman, L. J. A., Thomas, L. F., Noordam, R., Benner, C., Gormley, P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-021-00990-0 · Cited by 398
Migraine: integrated approaches to clinical management and emerging treatments
Ashina, M., Buse, D. C., Ashina, H., Pozo-Rosich, P., Peres, M. F. P., Lee, M. J., Terwindt, G. M., Halker Singh, R., Tassorelli, C., Do, T. P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32342-4 · Cited by 305
Metadata
- Authors
- Kuca, B., Silberstein, S. D., Wietecha, L., Berg, P. H., Dozier, G., Lipton, R. B., on behalf of the COL MIG-301 Study Group, COL MIG-301 Study Group, Adams, M., Alftine, C., Allaw, M., Allen, L., Ampajwala, M., Bakhtari, L., Bhasker, K., Bird, D., Bolshoun, D., Brown, J., Brownstone, P., Bruce, T., Burke, D., Chuang, R., Conrady, R., Davis, B., Davis, C., Dawson, M., Desantis, D., Dushkin, H., Ellison, W., Ervin, J., Essink, B., Fakhouri, I., Fiel, T., Fitzgibbons, W., Francyk, D., Geisberg, H., Geohas, J., Giep, S., Glover, R., Godbole, N., Grainger, W., Griffin, C., Halpern, S., Han, M., Hiotis, L., Huffman, C., Hummel, M., Hurley, D., Inzerello, A., Jagielo, T., Jennings, W., Kaiser, S., Kay, J., Khalifa, A., Kirby, W., Klein, J., Klein, T., Kopp, J., Kotek, L., Korff, G., Kutner, M., Lending, R., Lentino, J., Lenzmeier, T., Lesch, D., Levins, P., Lewis, M., Lowy, A., Lunn, C., Maw, K., McConnehey, B., Mehra, V., Mehta, P., Meli, J., Mirza, L., Molin, C., Molpus, R., Murray, L., Noss, M., Palatnik, M., Rauzi, F., Razzaque, N., Reynolds, M., Riesenberg, R., Riffer, E., Rodriguez, A., Schlosser, D., Schumacher, D., Severance, R., Shockey, G., Singer, R., Smith, W., Stewart, J., Stolyar, A., Tejada, A., Tharenos, L., Titus, J., Turner, M., Turner, M., Vallanat, A., Verma, S., Vollbracht, S., Wilks, K., Williams, H., Williams, W., & Wolf, T.
- Venue
- Neurology
- Published
- 2018-12-11
- Volume
- 91
- Issue
- 24
- Pages
- e2222-e2232
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2901869599
- Cited by
- 270
- References
- 20
- FWCI
- 26.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. https://app.cochat.ai/papers/10.1212/wnl.0000000000006641
- The paper
- Kuca, B., Silberstein, S. D., Wietecha, L., Berg, P. H., Dozier, G., Lipton, R. B., on behalf of the COL MIG-301 Study Group, COL MIG-301 Study Group, Adams, M., Alftine, C., Allaw, M., Allen, L., Ampajwala, M., Bakhtari, L., Bhasker, K., Bird, D., Bolshoun, D., Brown, J., Brownstone, P., . . . Wolf, T. (2018). Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. https://doi.org/10.1212/wnl.0000000000006641
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.